Capital efficiency in cardiovascular outcomes trials

Cardiovascular outcomes trials (CVOTs) are among the most complex and resource-intensive studies in late-stage drug development, making operational efficiency a critical driver of program value. New Tufts Center for the Study of Drug Development (CSDD) research shows that integrating clinical research and manufacturing functions in Phase III CVOTs can significantly increase expected net present value by accelerating timelines, improving event accrual and reducing execution risk.

The analysis highlights proactive management of major adverse cardiovascular event (MACE) accrual—through optimized country, site and patient selection—as a key lever for enhancing trial performance. As cardiometabolic pipelines continue to expand, integrated execution strategies can help sponsors maximize asset value, improve return on investment and bring innovative therapies to patients sooner.

Download the white paper to learn how we can enable your CVOT to achieve faster timelines, lower costs and greater returns.